Japan’s CellSeed, MNCs To Market Cornea Tissue Technique Globally
This article was originally published in PharmAsia News
Japan's CellSeed and three foreign companies have united to market globally the regenerative cornea replacement tissue CellSeed developed. CellSeed, a spinoff from Tokyo Women's Medical University where the technique was developed, has trials under way in France. The three partners are Teva Pharmaceutical Industries of Israel, Genesis Pharma of Greece and Orphan Australia of Australia, which together plan to market the tissue in more than 12 countries as soon as 2011. (Click here for more - a subscription may be required
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.